Udayavni Special

India likely to waive customs duty on COVID-19 vaccine imports


Team Udayavani, Apr 20, 2021, 12:17 PM IST

New Delhi: The government is likely to waive 10 percent customs duty levied on imported vaccines in a bid to keep low the cost of overseas vaccines that are being eyed to supplement domestically made shots ahead of opening COVID-19 vaccination to all citizens over 18 years of age, sources said.

While Russia”s Sputnik V vaccines are due to arrive this month or latest by next month, manufacturers like Moderna and Johnson and Johnson have been urged to seek emergency use approval in India.

The government presently levies 10 percent customs or import duty plus a 16.5 percent I-GST and social welfare surcharge on vaccines coming from overseas. These taxes would make the imported vaccines costlier than the ones made by the Serum Institute of India (SII) and Bharat Biotech.

“A customs duty waiver is being considered,” a source aware of the matter said.

Another source said a decision is likely to be made “very soon.”

The government earlier this month allowed emergency use of imported vaccines to curb the spread of coronavirus infections. With 2.59 lakh new infections, the caseload has crossed 1.53 crore, making India the second-worst affected nation after the US, which has reported more than 3.1 crore infections. India’s deaths from COVID-19 rose by a record 1,761 to over 1.8 lakh.

Sources said the discussion on duty exemption on vaccines started sometime in December last year when overseas manufacturers such as Pfizer sought approval to supply its vaccines to India.

The finance ministry and its indirect tax collection arm had done some preliminary calculations on the implications of a duty waiver but a decision was put off until the government approved the use of imported vaccines, they said.

The government, which on Monday allowed citizens over the age of 18 years to receive COVID-19 vaccinations “from May 1, currently regulates the sale and purchase of all Covid shots in the country.

Under the third phase of its vaccination strategy, manufacturers will be required to supply 50 percent of their monthly doses to the government and the rest to state governments or the open market.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Why lie on SC order on national task force, Fadnavis asks Sena

U’khand has highest COVID fatality rate among Himalayan states: NGO

Practically impossible to provide oxygen to other states due to rising COVID cases: Kerala CM tells Centre

Nalin Kumar Kateel donates Rs. 2.50Cr to Dakshina Kannada for Covid-19 relief

‘Karnataka plans to open triaging centres in Dakshina Kannada, 9 other dists’

Kolkata Durga idol makers anxious about business in second Covid-hit year

Users not accepting new privacy terms to face limited functionality: WhatsApp



Related Articles More

Reports state China probed weaponising SARS‑CoV‑2 viruses in 2015

COVID-19: India records 3,66,161 fresh cases, 3,754 more fatalities

Vaccination of 18-44 age group: Construction workers, kin to get COVID jab in first phase

India records 4,03,738 new COVID-19 cases, 2,42,362 deaths

Karnataka reports 47,563 COVID-19 cases, 482 deaths

MUST WATCH

Kuwait ship carrying medical oxygen arrives at Navamangalore port

Dr Dinesh Shetty | Current Situation in Karnataka | Udayavani

Young man comes to buy vegetables wearing doctor’s apron

Unique Safety Method to save from Police

Udayavani 10 -May -2021 News Bulletin

Latest Additions

Why lie on SC order on national task force, Fadnavis asks Sena

Armed forces helping admin in fight against COVID-19: Centre to HC

U’khand has highest COVID fatality rate among Himalayan states: NGO

Twitter handle of J-K Lt Governor suspended briefly, officials cite technical error

Practically impossible to provide oxygen to other states due to rising COVID cases: Kerala CM tells Centre

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.